Abstract-HIMF (hypoxia-induced mitogenic factor/found in inflammatory zone 1/resistin like α) is a secretory and cytokine-like protein and serves as a critical stimulator of hypoxia-induced pulmonary hypertension. With a role for HIMF in heart disease unknown, we explored the possible roles for HIMF in cardiac hypertrophy by overexpressing and knocking down HIMF in cardiomyocytes and characterizing HIMF gene (himf) knockout mice. We found that HIMF mRNA and protein levels were upregulated in phenylephrine-stimulated cardiomyocyte hypertrophy and our mouse model of transverse aortic constriction-induced cardiac hypertrophy, as well as in human hearts with dilated cardiomyopathy. Furthermore, HIMF overexpression could induce cardiomyocyte hypertrophy, as characterized by elevated protein expression of hypertrophic biomarkers (ANP [atrial natriuretic peptide] and β-MHC [myosin heavy chain-β]) and increased cell-surface area compared with controls. Conversely, HIMF knockdown prevented phenylephrineinduced cardiomyocyte hypertrophy and himf ablation in knockout mice significantly attenuated transverse aortic constriction-induced hypertrophic remodeling and cardiac dysfunction. HIMF overexpression increased the cytosolic Ca 2+ concentration and activated the CaN-NFAT (calcineurin-nuclear factor of activated T cell) and MAPK (mitogenactivated protein kinase) pathways; this effect could be prevented by reducing cytosolic Ca 2+ concentration with L-type Ca 2+ channel blocker nifedipine or inhibiting the CaSR (Ca 2+ sensing receptor) with Calhex 231. Furthermore, HIMF overexpression increased HIF-1α (hypoxia-inducible factor) expression in neonatal rat ventricular myocytes, and HIMF knockout inhibited HIF-1α upregulation in transverse aortic constriction mice. Knockdown of HIF-1α attenuated HIMF-induced cardiomyocyte hypertrophy. In conclusion, HIMF has a critical role in the development of cardiac hypertrophy, and targeting HIMF may represent a potential therapeutic strategy. (Hypertension. 2018;72:331-342.
C
ardiac hypertrophy characterized by enlarged cardiomyocytes, increased protein synthesis, reactivated fetal genes, cytoskeleton remodeling, and fibrosis is initially an adaptive response of the heart to pressure or volume overload. However, prolonged hypertrophy is associated with a high risk of cardiovascular mortality [1] [2] [3] : pathological hypertrophy is an initial risk factor for advanced-stage heart failure (HF), a leading cause of death worldwide, and an independent risk factor for sudden death because of lethal cardiac arrhythmia. 4, 5 Preventing the development of hypertrophy is crucial for reducing cardiovascular events. However, despite advances in our understanding of hypertrophy development during the past 3 decades, 1, 2, 6 the underlying mechanisms are largely unknown, and effective therapeutic strategies are urgently needed.
HIMF (hypoxia-induced mitogenic factor/found in inflammatory zone 1/resistin like α) is a secretory and cytokine-like protein originally discovered in a mouse model of hypoxiainduced pulmonary hypertension. 7 HIMF has mitogenic, angiogenic, vasoconstrictive, and chemokine-like properties that are all associated with pathological pulmonary conditions, including vasoconstriction, vascular remodeling, inflammation, and fibrosis. 7, 8 HIMF activates multiple signaling pathways (including those mediated by PI3K [phosphatidylinositol 3-kinase]/Akt [serine/threonine-protein kinase], ERK1/2 (extracellular regulated MAP kinases 1/2), and Notch1) and elicits the production of inflammatory factors that initiate proliferation, migration, and differentiation of pulmonary vascular smooth muscle cells, endothelial cells, and myofibroblasts.
These functions result in vascular remodeling and, thus, the development of pulmonary hypertension. [9] [10] [11] HIMF can also induce pulmonary vasoconstriction by stimulating intracellular Ca 2+ release in human pulmonary artery smooth muscle cells (PASMCs) via the PLC (phosphatidylinositol-phospholipase C) signaling pathway in an IP 3 (inositol triphosphate) and tyrosine phosphorylation-dependent manner, leading to pulmonary hypertension. 12 A recent study identified HIMF as a noncanonical ligand of the extracellular CaSR (Ca 2+ -sensing receptor) in PASMCs. 13 HIMF-CaSR binding induces PASMC proliferation and pulmonary hypertension on hypoxia stimulation. 13 HIMF protein is mainly expressed in lung, white adipose tissue, and heart, 14 but a possible role for HIMF in heart disease is unknown. Cardiac hypertrophy characterized by ventricular remodeling shares many pathological similarities with hypoxia-induced pulmonary hypertension. [15] [16] [17] [18] The main pathological stimulators for HIMF production in the lunghypoxia and inflammation-are widely present in hypertrophic heart tissue. Hypoxia is a prominent feature of cardiac hypertrophy because of increased oxygen consumption by the heart and a relatively reduced blood supply as a result of imbalanced heart tissue and vasculature growth. Inflammation is also a notable pathological change in heart tissue that makes a critical contribution to the pathogenesis of hypertrophy.
Here, we addressed the hypothesis that HIMF has a critical role in cardiac hypertrophy. We first examined whether HIMF expression was increased during cardiac hypertrophy. We then manipulated HIMF expression in cardiomyocytes and used himf knockout mice to investigate the role of HIMF in hypertrophy and explore the underlying mechanisms.
Methods
The data that support the findings of this study are available from the author Gang Wang (wangg@szu.edu.cn) on reasonable request. Detailed methods are available in the Data Supplement and Methods section.
Animals
Sprague-Dawley rats were obtained from the Animal Center of the Southern Medical University, China. All animal protocols were approved by the Institutional Care and Ethical Committee of Shenzhen University and followed the procedures outlined in the Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication number. 85-23, revised 1996). HIMF knockout mice (himf −/− on a C57BL/6J background) were procured from the Nanjing Biomedical Research Institute of Nanjing University, China.
Human Heart Samples
All human studies were performed in accordance with the Declaration of Helsinki. Human heart samples were obtained via protocols approved by Zhongshan People's Hospital, China, Institutional Review Boards on Human Subjects. Patients with advanced cardiomyopathy gave informed consent for the collection of sample tissue according to an approved Institutional Review Board protocol. At the time of heart transplantation, tissues were procured, flash-frozen, and stored at −80°C until use.
Neonatal Rat Ventricular Myocytes Culture
Neonatal rat ventricular myocytes (NRVMs) were isolated and cultured from 1-to 2-day-old Sprague-Dawley rats, as previously described.
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Transverse Aortic Constriction C57BL/6 male mice (7-8 weeks, 18-22 g) were randomly divided into 4 groups: sham and transverse aortic constriction (TAC) with or without HIMF knockout condition. The TAC model was produced as previously described.
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Statistical Analyses
Data are presented as the means±SD. Statistical analyses between 2 groups were performed by unpaired Student t test. Differences between multiple groups were tested by 1-way ANOVA, and levels of significance were determined using Bonferroni multiple comparisons test (GraphPad Prism 6 Software Inc, San Diego, CA). In all cases, P<0.05 was considered statistically significant.
Results
HIMF Expression Is Upregulated in Pathological Cardiac Hypertrophy
We first explored HIMF expression during cardiac hypertrophy in phenylephrine-induced cardiomyocyte hypertrophy and in a pressure overload (TAC)-induced cardiac hypertrophy mouse model. NRVM stimulation with 100 µmol/L phenylephrine for 24 hours significantly increased the HIMF mRNA and protein levels ( Figure 1A ; Figure S3A ). The secreted HIMF in the culture medium of cardiomyocytes was also remarkably increased by phenylephrine stimulation ( Figure S3B ). Consistently, HIMF mRNA and protein expression in hearts from TAC mice (9 weeks) were markedly increased relative to control ( Figure 1A ; Figure S3A ). To explore the clinical relevance, HIMF expression was analyzed in heart tissue samples isolated from patients with idiopathic dilated cardiomyopathy. Here, we found the HIMF expression significantly increased compared with healthy human heart control tissue ( Figure 1B) . The protein levels of ANP (atrial natriuretic peptide) and β-MHC (myosin heavy chain-β), the biomarkers for cardiac hypertrophy, were remarkably increased in phenylephrinestimulated cardiomyocytes, TAC mouse hearts, and patient hearts with idiopathic dilated cardiomyopathy compared with control ( Figure 1A and 1B). These data indicate that HIMF expression is upregulated in pathological cardiac hypertrophy.
The other possible mechanisms involving in HIMF upregulation besides α-adrenergic stimulation (phenylephrine) in cardiac hypertrophy were also explored. We found that isoproterenol (1 µmol/L, 24 hours), the β-adrenergic agonist, increased HIMF expression in NRVMs ( Figure S4A ), as phenylephrine did, but to a less extent (phenylephrine and isoproterenol increased HIMF protein level by 128% and 69%, respectively). However, Ang II (angiotensin II; 100 nmol/L, 24 hours), another strong stimulator for cardiac remodeling, had no effect on HIMF expression ( Figure S4B ) despite its increased ANP and β-MHC expression ( Figure S4B ). Hypoxia is a prominent pathological feature of cardiac hypertrophy. The expression of HIMF, as well as HIF-1α (hypoxia-inducible factor-1α), was remarkably increased when the NRVMs were exposed to hypoxia for 24 hours ( Figure S4C ).
High HIMF Expression Induces Cardiomyocyte Hypertrophy
We next examined the possible link between HIMF expression levels and development of hypertrophy by exogenously overexpressing HIMF in cultured NRVMs. Infection of cardiomyocytes with an HIMF adenovirus increased the HIMF protein levels by 2.70±0.67 fold ( Figure 1C ), without affecting cell viability (data not shown). The protein levels of ANP and β-MHC, the biomarkers for hypertrophy, were significantly increased in HIMF adenovirus cells compared with Ad-GFP (adenovirus green fluorescent protein) controls ( Figure 1C) . Consistently, the cell size (indicated as the cell-surface area) markedly increased as a result of HIMF overexpression ( Figure 1D ). These results indicate that high HIMF expression can induce cardiomyocyte hypertrophy in cultured NRVMs.
We next explored whether increased HIMF expression participates in phenylephrine-induced cardiomyocyte hypertrophy. Here, we reduced HIMF expression by infecting cardiomyocytes with an HIMF RNA interference adenovirus (sh-HIMF [short hairpin RNA for HIMF]; Figure 1E ). We confirmed that phenylephrine induced cardiomyocyte hypertrophy, as verified by increased ANP and β-MHC protein levels ( Figure 1E ) and increased cell size ( Figure 1F ). In these cells, HIMF expression was significantly increased ( Figure 1E ). Knockdown of HIMF expression by ≈70% with sh-HIMF largely reduced phenylephrine-induced cardiomyocyte hypertrophy as ANP and β-MHC expression and the cell-surface area decreased ( Figure 1E and 1F). Furthermore, increasing HIMF expression exaggerated phenylephrine-induced cardiomyocyte hypertrophy, where ANP and β-MHC expression and the cell-surface area were further increased compared with the parameters in phenylephrine-stimulated cells ( Figure  S5A and S5B). These data indicate that HIMF contributes to phenylephrine-induced cardiomyocyte hypertrophy.
HIMF Knockout Attenuates TAC-Induced Cardiac Hypertrophy in Mice
We used HIMF knockout mice (himf −/− ) to monitor the role of HIMF in TAC-induced cardiac hypertrophy. Echocardiography demonstrated hypertrophy in wild-type (wt) mice 6 weeks after TAC, where the thicknesses of the left ventricular posterior wall at systole and left ventricular posterior wall at diastole were significantly increased in wt-TAC mice compared with shams ( Figure 2A and 2B). The systolic left ventricular internal dimension and diastolic left ventricular internal dimension were also increased 9 weeks after TAC ( Figure 2B ). Meanwhile, the cardiac contractile function indexed by the ejection fraction and left ventricular fractional shortening were significantly decreased 9 weeks after TAC compared with sham ( Figure 2B ). Cardiac hypertrophy in wt-TAC mice was further confirmed by the significant increase of the gross heart size ( Figure 2C ), and heart weight/body weight and lung weight/body weight ratios ( Figure 2D and 2E), and increased ANP and β-MHC protein levels ( Figure 2F ) as compared with shams. Measuring HIMF protein level in heart tissue ( Figure 2F ) and immunofluorescence of HIMF protein in heart slices ( Figure S6A ) demonstrate that HIMF expression in TAC mouse hearts was significantly increased relative to control. HIMF knockout confirmed by HIMF protein level and HIMF immunofluorescence ( Figure 2F ; Figure S6A ) attenuated the development of cardiac hypertrophy in TAC mice, where all the hypertrophic changes were remarkably reduced in himf −/− TAC mice compared with wt-TAC mice during cardiac hypertrophy. Notably, the cardiac function was maintained after TAC in himf −/− mice ( Figure 2B ). Furthermore, the development of fibrosis in heart after TAC in himf −/− mice was less severe than wt-TAC mice ( Figure 2C) . Accordingly, the impaired diastolic function indexed by the increase of the E-wave peak by A-wave peak ratio of diastolic filling and increased isovolumic relaxation time in TAC mice was largely improved by ablation of HIMF ( Figure S7A ). Tunnel staining indicates HIMF knockout reduced myocyte apoptosis -activated pathways are well-known pathological hypertrophic signals with critical roles during hypertrophy development and consequent HF. 21 A previous study in human PASMCs found that HIMF can stimulate intracellular Ca 2+ release. 12 To explore whether HIMF has a similar effect on intracellular Ca 2+ in cardiomyocytes, we examined the changes in resting cytosolic Ca ]cyt (F 340 nm/380 nm ) relative to the GFP control ( Figure 3C ). To exclude the possibility that GFP fluorescence may interfere with Fura-2 fluorescence, we checked the effect of recombinant HIMF applied exogenously on [Ca 2+ ]cyt in NRVMs. Here, we found that recombinant HIMF (50 ng/mL) similarly increased [Ca 2+ ]cyt in NRVMs ( Figure 3C ). The CaN-NFAT (calcineurin-nuclear factor of activated T cell) pathway is widely accepted as a Ca 2+ -dependent pathological pathway in hypertrophy. 22 Increases in intracellular Ca 2+ activate the phosphatase CaN, which dephosphorylates cytosolic NFAT to promote NFAT translocation to the nucleus; here, NFAT initiates transcription of hypertrophic genes. 23 The finding that HIMF increases [Ca 2+ ]cyt motivated us to explore whether HIMF can activate the CaN-NFAT signaling pathway. As expected, HIMF overexpression for 48 hours increased CaN-A phosphatase activity ( Figure 3D ) without markedly affecting its protein expression ( Figure 3E ). Concomitantly, HIMF overexpression increased the protein levels of nNFATc3 (nuclear NFATc3) and decreased the protein levels of cNFATc3 (cytosolic NFATc3) simultaneously ( Figure 3E ), indicating activation of the prohypertrophic CaN-NFAT pathway.
The MAPK (mitogen-activated protein kinase) pathway, which has a critical role in hypertrophy development, 1,2,24 can also be activated by calcium. 24 The interaction between calcium and CaM (calmodulin; Ca 2+ -CaM) activates MAPK-3 (MAPKKK) through PKC (protein kinase C), and consequently the 3 cascades of the MAPK pathway: ERK, JNK (c-Jun NH2-terminal kinase), and p38. 24 We found that the relative phosphorylation levels of ERK, JNK, and p38 were significantly increased in HIMF adenovirus cells relative to control (Figure 3F ), indicating HIMF-mediated activation of the MAPK pathway.
HIMF Activates the CaN-NFAT and MAPKs Pathways in Cardiac Hypertrophy
We next investigated the role of HIMF-mediated CaN-NFAT and MAPK pathway activation during hypertrophy in phenylephrine-stimulated cells and TAC mice. Consistent with previous studies, 25, 26 phenylephrine activated the CaN-NFAT and MAPK signaling pathways. CaN phosphatase activity ( Figure 4A ) and nNFATc3 protein levels ( Figure 4B ) were significantly increased, and cNFATc3 protein levels were decreased ( Figure 4B ) 24 hours after phenylephrine stimulation. The 3 MAPK cascades (ERK, JNK, and p38) were activated in a time-dependent manner. The phosphorylation of ERK, JNK, and p38 was dramatically increased 10 minutes after phenylephrine stimulation and gradually decreased to normal 60 minutes after phenylephrine stimulation ( Figure 4C ). This is consistent with previous reports. 25 We, thus, performed statistics of MAPKs at 10 minutes after phenylephrine stimulation. HIMF knockdown (sh-HIMF) decreased HIMF expression by ≈70% and suppressed the activation of CaN-NFAT ( Figure 4A and 4B) and MAPK pathways ( Figure 4C ). Similar results were found in TAC-induced cardiac hypertrophy, where the CaN-NFAT and MAPKs pathways were activated in wt-TAC mice and substantially inhibited in himf −/− TAC mice ( Figure 4A , 4D, and 4E). These data suggest that HIMF participates in activating the CaN-NFAT and MAPK pathways in cardiac hypertrophy.
The changes of Ca 2+ homeostasis and contractility in cardiomyocytes from wt and himf −/− mice subjected to sham or TAC at 9 weeks were also explored. Consistent with the previous study, the amplitude of systolic Ca 2+ transient and myocyte contraction (indexed by the cell shortening) were remarkably decreased in TAC cardiomyocytes compared with sham ( Figure S9A, S9B, and S9D) . The half time of decay of Ca 2+ transient (t 50 ) was prolonged in TAC cardiomyocytes relative to sham ( Figure S9C ), suggesting SR Ca 2+ reuptake is impaired. 27 The protein levels of SERCA and pPLMBN were decreased ( Figure S9E ), indicating reduced SERCA activity. These data are consistent with the prolonged decay of Ca 
Nifedipine Inhibits HIMF-Induced Cardiac Hypertrophy
We investigated the causal relationship between activated Ca 2+ signaling pathways and HIMF-induced cardiac hypertrophy by inhibiting the Ca 2+ signals with nifedipine-a specific L-type Ca 2+ channel inhibitor that can prevent the development of hypertrophy in cells and animal models in TAC mice. 28, 29 Nifedipine pretreatment (5 μmol/L, applied 30 minutes before adenovirus infection) significantly inhibited the HIMFinduced increase of [Ca 2+ ]cyt ( Figure 5A ). Concomitantly, HIMF-induced activation of the CaN-NFAT ( Figure 5D and 5E) and MAPK pathways ( Figure 5F ) was suppressed.
Meanwhile, nifedipine pretreatment attenuated HIMFinduced cardiomyocyte hypertrophy, as indicated by the maintenance of ANP and β-MHC protein levels ( Figure 5C ), and the less increased cell-surface area compared with cells without nifedipine pretreatment ( Figure 5B ). These data collectively indicate that HIMF induces cardiac hypertrophy via a Ca 2+ -dependent mechanism.
Inhibiting the CaSR Attenuates HIMF-Induced Cardiomyocyte Hypertrophy
A recent study reported that HIMF is a noncanonical ligand of the CaSR in PASMCs. 13 CaSR mediates HIMF-induced proliferation of PASMCs and the development of pulmonary hypertension during hypoxia. 13 The CaSR is expressed in heart tissue, and several studies have linked it to the development of hypertrophy. 30, 31 We, thus, investigated whether the CaSR mediates HIMF-induced cardiac hypertrophy. We pretreated NRVMs with the specific CaSR inhibitor, Calhex 231 (1 µmol/L) for 30 minutes before HIMF adenovirus or Ad-GFP infection. HIMF overexpression increased CaSR expression ( Figure S10 ) and induced hypertrophic growth of the cardiomyocytes ( Figure 5B ). Pretreatment with Calhex 231 attenuated HIMF-induced hypertrophic remodeling, where the protein levels of ANP and β-MHC ( Figure 5C ) and the cellsurface area were significantly decreased in HIMF overexpressed cells with Calhex 231 pretreatment ( Figure 5B ). The [Ca 2+ ]cyt and CaN-NFAT and MAPK pathways were also significantly suppressed by Calhex 231 pretreatment ( Figure 5A and 5D-5F). These results indicate that the CaSR mediates HIMF-induced activation of the Ca 2+ -dependent signaling pathways and cardiac hypertrophy.
HIF-1α Participates in HIMF-Induced Cardiac Hypertrophy
HIF-1α is a central transcriptional regulator of hypoxic response and involves in HIMF-mediated hypoxic pulmonary hypertension. 32 We, thus, explored the possible role of HIF-1α in HIMF-induced cardiac hypertrophy. Consistent with the previous studies, 22 the protein expression of HIF-1α in TAC mice was significantly increased compared with sham ( Figure 6A ). HIMF knockout prevented HIF-1α increase by TAC ( Figure 6A ). HIMF overexpression in NRVMs increased HIF-1α protein level ( Figure 6B ). Knocking down HIF-1α by 68.4% with HIF-1α-targeted small-interfering RNA inhibited HIMF overexpression-induced cardiomyocyte hypertrophy, as the expression of ANP and β-MHC (Figure 6B) , as well as cell size was decreased ( Figure 6C ). The data indicate HIF-1α mediates HIMF-induced cardiac hypertrophy.
Discussion Critical Role for HIMF in Pathological Cardiac Hypertrophy
HIMF is a secreted protein involved in various lung diseases, including hypoxic pulmonary hypertension, 7 allergic airway ) , and nNFATc3 (nuclear NFATc3). GAPDH was used as an internal control of CaN and cNFATc3, and lamin A as an internal control of nNFATc3. n=3/group. F, Representative immunoblots and statistics of phosphorylated ERK (extracellular regulated MAP kinase), JNK (c-Jun NH2-terminal kinase), and p38 and total ERK, JNK, and p38. n=3/group. *P<0.05, **P<0.01. disease, 7, 14 and bleomycin-induced lung fibrosis. 33 Although HIMF is expressed in the heart, its role in heart disease is unknown. This study demonstrates that HIMF is upregulated in cardiac hypertrophy by activation of α-and β-adrenergic receptors, as well as hypoxia, a prominent feature of cardiac hypertrophy. Furthermore, we provide evidence linking the upregulated HIMF with the development of cardiac hypertrophy. First, upregulating HIMF protein levels stimulate remarkable hypertrophic growth of NRVMs. Second, knocking down HIMF increased by phenylephrine stimulation significantly inhibits phenylephrine-induced cardiomyocyte hypertrophy, whereas overexpressing HIMF exaggerates phenylephrine-induced cardiomyocyte hypertrophy. Finally, deletion of himf gene expression in mice attenuates TACinduced cardiac hypertrophy and impaired cardiac function. Therefore, we conclude that upregulated HIMF expression contributes to hypertrophic remodeling and cardiac dysfunction in cardiac hypertrophy.
It is well-known that cardiac fibrosis is a significant manifestation in cardiac hypertrophy, which causes the impairment of diastolic function and increased susceptibility to arrhythmia. 34, 35 This study demonstrates that ablation of HIMF has a pronounced therapeutic effect on cardiac fibrosis and impairment of diastolic function in TAC mice. Previous studies demonstrated that HIMF induces myofibroblast differentiation in lung fibroblast cultures. 36 Addressing whether HIMF has similar effect on cardiac fibroblasts would be important for understanding HIMF-induced cardiac fibrosis and warrant future study. 
CaSR-Mediated
HIF-1α Mediates HIMF-Induced Cardiac Hypertrophy
HIF-1α is a central transcriptional regulator of hypoxic response and tightly linked to HIMF-mediated hypoxic pulmonary hypertension. 32 HIF-1α signal can be activated in cardiomyocytes on hypoxia stimulation, resulting in hypertrophic remodeling. 40 Increased HIF-1α protein levels have also been found in samples from human patients with cardiomyopathy, which is linked to the unfavorable consequences of the heart disease. 41 In this study, we found that HIF-1α expression is increased in TAC mice, and HIMF knockout prevented TAC-induced HIF-1α upregulation. Furthermore, HIMF overexpression increased HIF-1α protein level in cultured cardiomyocytes, whereas knockdown of HIF-1α largely inhibited HIMF-induced cardiomyocyte hypertrophy. The data indicate that HIF-1α is a downstream signal mediating HIMF-induced cardiac hypertrophy.
Previous studies indicate that HIF-1α can regulate intracellular Ca 2+ homeostasis and activate CaN pathway. 40 MAPK pathways have also been shown to regulate HIF-1α signal. 42 In this consideration, HIMF-activated pathways have crosstalk and amplify the role of HIMF in cardiac hypertrophy ( Figure 6D ).
Perspectives
Persistent hypertrophy develops to HF by stimulating multiple pathological processes, including metabolic dysfunction, oxidative stress, inflammation, and apoptosis. Because HF is a multifactorial effect, there are no treatments available to cure HF till now. Therefore, attenuating the development of hypertrophy before HF represents a promising therapeutic strategy for HF. The findings in this study demonstrate for the first time the critical role of HIMF in the development of cardiac hypertrophy and thus identify HIMF as a potential therapeutic target for cardiac hypertrophy and consequent HF. This study verified that HIMF knockout attenuates cardiac hypertrophy and improves cardiac function. However, gene therapy has the limitations of potential side effects and difficulty in manipulation. As HIMF is a secreted protein, its effect can be readily blocked exogenously by application of an anti-HIMF antibody. Furthermore, our data indicate that CaSR mediates HIMF-induced cardiac hypertrophy, suggesting that the binding motif of extracellular CaSR for HIMF can be therapeutically exploitable. These approaches may have the potential to be translated to clinical therapy and warrant future study.
